Clinical trials: Parkinson's Plus Syndromes
Parkinson's Disease, Parkinsonian Syndromes
Temporal Interference Noninvasive Deep Brain Stimulation for Idiopathic Parkinson's Disease and Parkinsonian Syndromes: Effects and Target Exploration
This study aims to explore the therapeutic effects of noninvasive deep brain electrical stimulation using temporal interference principles (Temporal Interference Stimulation, TIS) on both motor and non-motor symptoms in patients…
- Trial name
- NCT07698236
- Testing
- AB Temporal Interference Stimulation, BA Temporal Interference Stimulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Parkinson Disease, Dyskinesia, Medication-Induced
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
This is a randomized, double-blind, placebo-controlled, crossover, proof-of-concept Phase 2 study to test efficacy and safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease subjects with levodopa-induced dyskinesia.
- Conditions
- Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use
- Trial name
- NCT04147949
- Testing
- AV-101
- Volunteers
- 20 people
- Sponsor
- VistaGen Therapeutics, Inc.
Communication Disorder, Healthy
Central Mechanisms in Speech Motor Control Studied With H215O PET
Positron Emission Tomography (PET) is a technique used to investigate the functional activity of the brain. The PET technique allows doctors to study the normal biochemical and metabolic processes of the central nervous system of…
- Conditions
- Communication Disorder, Healthy, Stuttering, Tourette Syndrome
- Trial name
- NCT00001308
- Where
- United States
- Volunteers
- 1,163 people, healthy volunteers welcome
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Parkinson Disease, Movement Disorders
Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study determined if a lower dose (5 millicuries) would suffice.
- Trial name
- NCT05636852
- Testing
- Altropane (123I) Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- GE Healthcare
Multiple System Atrophy, Progressive Supranuclear Palsy
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus'…
- Trial name
- NCT00211224
- Testing
- Riluzole
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- King's College London
Parkinsonian Syndrome
A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease
This study involves study participants who have been clinically diagnosed with parkinsonian syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian syndrome or exposure to environmental toxins…
- Trial name
- NCT00117819
- Testing
- [123I]ß CIT and SPECT imaging
- Where
- United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Parkinson's Disease, Parkinsonian Syndrome
A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease
The goal of this study is to investigate neurophysiologic tests that have the potential of serving as screening tools for Parkinson's disease.
- Trial name
- NCT00117195
- Testing
- Automated Neuropsychological Assessment Matrix
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD)…
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- NCT07509125
- Testing
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Parkinson Disease
11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes
To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh compound B (PiB) retention, to the progression of cognitive impairments in patients with Parkinson's disease(PD).
- Trial name
- NCT03555292
- Testing
- 11C-PiB
- Where
- 3 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Oriental Neurosurgery Evidence-Based-Study Team
Parkinsonian Syndrome
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is…
- Trial name
- NCT00129675
- Testing
- [123I]ß CIT
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Institute for Neurodegenerative Disorders
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)
This pilot study evaluated the safety, tolerability, and exploratory epigenetic outcomes of a single same-day autologous bone marrow procedure in adults with Parkinson's disease (PD) or Parkinson-plus syndromes (PPS).
- Trial name
- SPARC-PD (NCT07751640)
- Testing
- Autologous Bone Marrow Aspirate (BMA) and Bone Marrow Aspirate Concentrate (BMAC)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Apeiron Research Center
Dyskinesia, Drug-Induced, Parkinson Disease
Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease
Using a within-subject cross-over design, we will include 20 patients with Parkinson disease (PD) and peak-of-dose dyskinesia. Patients will be studied after withdrawal from their normal dopaminergic medication.
- Trial name
- NCT03354455
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Parkinson's Disease, Movement Disorder Syndrome
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.
- Trial name
- NCT00199433
- Testing
- Istradefylline (KW-6002)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Kyowa Kirin, Inc.
Pisa Syndrome, Parkinson' Disease
Prismatic Lenses in the Pisa Syndrome
Non-pharmacological interventional pilot study on the effect of prismatic glasses for the improvement of Pisa syndrome in Parkinson's disease.
- Trial name
- NCT03737773
- Testing
- glasses (prismatic lenses), glasses (neutral)
- Volunteers
- 40 people
- Sponsor
- Neuromed IRCCS
Parkinson Disease, Parkinson Disease, Secondary
Accelerated Temporal Interference Stimulation on Bilateral Subthalamic Nucleus for Parkinson's Disease and Secondary Parkinson's Syndrome
This clinical trial will evaluate the efficacy of accelerated Temporal Interference Stimulation (TIS) as a therapeutic intervention for individuals diagnosed with Parkinson's disease or secondary Parkinson's syndrome.
- Trial name
- NCT07568067
- Testing
- Temporal Interference Stimulation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ke Dong, MD
Parkinson Disease, Parkinson's Syndrome
Evaluation of the Uses of a Digital-assisted Self-rehabilitation Device (TELE-PARK)
Evaluate the use by the patient and his family and professional environment of a self-rehabilitation device with follow-up in tele-rehabilitation in people with Parkinson's disease taking into account the different actors within…
- Trial name
- TELE-PARK (NCT03667456)
- Testing
- Self-rehabilitation by digital support
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Pôle Saint Hélier
Progressive Supranuclear Palsy, Cortical Basal Ganglionic Degeneration
tDCS as Treatment for Motor Function
Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation.
- Conditions
- Progressive Supranuclear Palsy, Cortical Basal Ganglionic Degeneration, Parkinson Disease
- Trial name
- PSP (NCT07291687)
- Testing
- Transcranial direct current stimulation (TDCS), Stimulation Arm
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Baycrest
Parkinson Disease, Dementia With Lewy Bodies
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Study goal: The goal of this prospective head to head comparison is to evaluate the effectiveness of [18F]-MFBG PET in assessing cardiac innervation, comparing it with [123I]-MIBG SPECT The study's primary focus is on…
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, MSA - Multiple System Atrophy, Alzheimer Disease
- Trial name
- NCT06120049
- Testing
- [18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT
- Where
- 2 sites in Belgium
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences